Clover Health Investments has delivered notice to the Centers for Medicare and Medicaid Services that it will exit the CMS ACO REACH Program at the end of the 2023 performance year. Written notification will also be sent to all participating physicians in accordance with CMS requirements. The decision will have no impact on its ACO REACH beneficiaries, and Clover will continue to fulfill all of its obligations under the ACO REACH Program for the 2023 performance year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLOV:
- Clover Health price target lowered to $1 from $1.50 at Citi
- Clover Health price target lowered to $2 from $3 at Canaccord
- Clover Health reports Q3 revenue $482.07M, consensus $494.6M
- Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance
- Clover Health options imply 11.6% move in share price post-earnings
